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K-ras mutation occurs in 40-50% of human colorectal adenomas and carcinomas, but its contribution to intestinal tumorigenesis in vivo is unclear. We developed K-ras V12 transgenic mice that were crossed with Ah-Cre mice to generate K-ras V12 /Cre mice, which showed bnaphthoflavone-induction of Cre-mediated LoxP recombination that activated intestinal expression of K-ras V12 4A and 4B transcripts and proteins. Only very occasional intestinal adenomas were observed in b-naphthoflavonetreated K-ras V12 /Cre mice aged up to 2 years, suggesting that mutated K-ras expression alone does not significantly initiate intestinal tumourigenesis. To investigate the effects of mutated K-ras on DNA mismatch repair (MMR)-deficient intestinal tumour formation, these mice were crossed with Msh2 2/2 mice to generate K-ras V12 /Cre/ Msh2 2/2 offspring. After b-naphthoflavone treatment, K-ras V12 /Cre/Msh2 2/2 mice showed reduced average lifespan of 17.375.0 weeks from 26.976.8 (control Msh2 2/2 mice) (Po0.01). They demonstrated increased adenomas in the small intestine from 1.41 (Msh2 2/2 controls) to 7.75 per mouse (increased fivefold, Po0.01). In the large intestine, very few adenomas were found in Msh2 2/2 mice (0.13 per mouse) whereas K-ras V12 /Cre/Msh2 2/2 mice produced 2.70 adenomas per mouse (increased 20-fold, Po0.01). Over 80% adenomas from K-ras V12 /Cre/ Msh2 2/2 mice showed transgene recombination with expression of K-ras V12 4A and 4B transcripts and proteins. Sequencing of endogenous murine K-ras showed mutations in two out of 10 tumours examined from Msh2 2/2 mice, but no mutations in 17 tumours from K-ras V12 /Cre/ Msh2 2/2 mice. Expression of K-ras V12 in tumours caused activation of the mitogen-activated protein kinase and Akt/protein kinase B signaling pathways, demonstrated by phosphorylation of p44MAPK, Akt and GSK3b, as well as transcriptional upregulation of Pem, Tcl-1 and Trap1a genes (known targets of K-ras V12 expression in stem cells). Thus, mutated K-ras cooperates
Introduction
Colorectal tumour formation involves progression from normal epithelium to adenomas to carcinomas associated with multiple genetic and epigenetic alterations (Kinzler and Vogelstein, 1996) . K-ras mutation occurs in 40-50% of human colorectal adenomas and carcinomas, but how oncogenic K-ras contributes to or modulates the processes of intestinal tumour formation in vivo is unclear (Barbacid, 1987) . K-ras mutations may be found at all stages of colorectal pre-neoplastic and neoplastic lesions, including dysplastic aberrant crypt foci (microadenomas) (Shivapurkar et al., 1997) and hyperplastic polyps (Otori et al., 1997) , as well as in apparently normal large intestinal epithelium taken from tumour-bearing colons (Morris et al., 1996; Yamada et al., 2005) . K-ras mutations are associated with increased size and dysplasia in adenomas, suggesting that they may be permissive for growth disorder early in tumorigenesis (Malumbres and Barbacid, 2003) . Mutation of the K-ras gene typically occurs at either codons 12 or 13 (or occasionally at codon 61), with the codon 12 glycine to valine substitution being the most aggressive mutation associated with poor prognosis (Andreyev et al., 2001 ). These mutations reduce or abolish the protein's intrinsic GTPase activity when complexed with GAPs, tending to lock K-Ras in a GTP bound conformation that is constitutively active (Barbacid, 1987) . This mutational activation of ras has several effects on cells in vitro and in vivo, including the establishment of the transformed phenotype, anchorage-independent growth, focus formation, increased proliferation, tumorigenic potential, changes in differentiation and altered susceptibility to apoptosis (Spandidos and Wilkie, 1984; Arends et al., 1993 Arends et al., , 1994 Brooks et al., 2001; James et al., 2003; Plowman et al., 2003 Plowman et al., , 2006a .
Inherited mutations in DNA mismatch repair (MMR) genes in humans are directly involved in the aetiology of hereditary non-polyposis colorectal cancer syndrome (HNPCC), and confer pre-disposition to colorectal and other tumours (Arends and Frayling, 2004) . The primary function of the MMR system is to eliminate base-to-base mismatches and insertion-deletion (in-del) loops that arise during DNA replication. Base-to-base mismatches involve the inappropriate substitution of one base for another and typically occur within sections of non-repetitive DNA, whereas in-del loops usually involve the loss or gain of repetitive sequence units such as (A)n, (CA)n repeats or other microsatellites, giving rise to microsatellite instability in MMR-defective cells. In mammals, mismatch or in-del loop recognition is attributed to heterodimeric protein complexes of MutS homologues, MSH2-MSH3 and MSH2-MSH6, which interact with a heterodimer of two MutL homologues, MLH1-PMS2 and MLH1-PMS1 (Toft and Arends, 1998; Jiricny and Nystrom-Lahti, 2000; Frayling et al., 2005) . As loss of MSH2 inactivates the activity of mismatch and in-del loop recognition heterodimers, MSH2 deficiency causes strong cancer predisposition in both mice and humans (de Wind et al., 1995 (de Wind et al., , 1998 Reitmair et al., 1995 Reitmair et al., , 1996 Toft et al., 1998 Toft et al., , 1999 Toft et al., , 2002 .
To clarify the role of expression of mutated K-ras in intestinal tumour development and progression in vivo, we developed and characterized mice with a transgene allowing inducible intestinal crypt epithelial stem cell expression of K-ras V12 via a Cre/LoxP system. Only very occasional intestinal tumours were found in these mice over 1-2 years. Therefore, we crossed these mice with Msh2-deficient mice to examine the effects of mutated K-ras on progression of MMR-deficient intestinal tumorigenesis. We found that intestinal expression of K-ras V12 in Msh2-null mice led to reduced survival and a marked increase in both small and large intestinal tumour (LIT) multiplicity, with the greater effect found on tumours of the colon and rectum, as in humans.
Results

Generation of conditional transgenic K-ras
V12 mice The conditional K-ras V12 expression transgene is based on the human K-ras V12 'minigene' sequence (with an activating mutation at codon 12 substituting valine for glycine) inserted into a vector with a floxed Neocontaining 'STOP' cassette separating the K-ras V12 'minigene' from the cytomegalovirus (CMV) promoter upstream. An internal ribosomal entry site (IRES) and enhanced green fluorescent protein (EGFP) sequence were inserted downstream to generate the final transgene construct called K-ras V12 shown in Figure 1 . The K-ras V12 'minigene' possesses intronic sequences allowing expression of both K-ras 4A and 4B transcript isoforms (Figure 1 ). The structure of the construct was confirmed by restriction enzyme digestion and DNA sequencing (data not shown). In order to confirm the correct functioning of the construct in vitro, the expression vector was transfected into HM1 murine embryonic stem (ES) cells, which were transiently transfected with a plasmid expressing Cre. Subsequent real time-polymerase chain reaction (RT-PCR) analysis showed expression of mutated human K-ras transcripts in these ES cells (data not shown). The K-ras V12 transgene construct was linearized by BamHI, purified and microinjected into fertilized FVB/N mouse oocytes. Two K-ras V12 founder mice were generated; one of which died and the other founder (shown to be K-ras V12 transgene positive) was crossed with B6 mice.
Analysis of the transgene copy number in K-ras V12 transgenic mice The surviving founder K-ras V12 transgene positive mouse (F0) was crossed with B6 mice, and after three positive offspring mice (identified by PCR assays for presence of CMV promoter, human K-ras, Neo and EGFP gene) was 52 (27 male and 25 female) (Figure 1) . Thus, the ratio of B6 to K-ras V12 offspring mice and the ratio of male to female offspring mice were both close to 1:1 (in a Mendelian ratio). The results suggested that the K-ras V12 transgene construct was integrated into a single site of an autosomal chromosome in the transgenic line.
The exon 3 DNA sequences of human and mouse K-ras genes are highly homologous with a DNA sequence difference of only two base pairs. A pair of PCR primers was designed to bind equally to both human and murine K-ras exon 3 DNA sequences and quantitative polymerase chain reaction (RT-qPCR) analysis showed the relative value of K-ras exon 3 copy number in B6 control mice was 2.0170.11 (mean7s.d.; n ¼ 6) and that in K-ras V12 transgenic mice was 2.9970.34 (n ¼ 6), indicating that B6 control mice have two endogenous copies of K-ras, but K-ras V12 transgenic mice have three copies, including the two normal endogenous murine K-ras genes and one extra copy of the K-ras V12 transgene construct integrated into the genome of the mice (Figure 1 ).
Conditional expression of Cre and K-ras
V12 in the intestines K-ras V12 transgene positive mice were crossed with AhCre mice that are capable of transient expression of Cre recombinase protein in the epithelial stem cells of the intestinal crypts following b-naphthoflavone (b-NF) intraperitoneal injection (Ireland et al., 2004) . This generated offspring mice positive for both conditional K-ras V12 and Ah-Cre transgenes, confirmed by PCRbased genotyping assays. The test group of 28 mice (positive for both K-ras V12 and Cre transgenes) were treated with b-NF (16 mg/kg per day for 6 days) to induce transient expression of Cre recombinase protein in intestinal epithelium. Using the PCR assay to detect recombination occurring at the two LoxP sites (flanking the 'STOP' cassette) which amplifies the DNA fragment between the two primers (one situated in the CMV promoter and the other situated in K-ras V12 exon 3), a B500 bp fragment (indicating LoxP recombination) was amplified from genomic DNA extracted from both large and small intestines, caecum, stomach and also from liver, lung and spleen (Figure 2 ). This showed that Cremediated recombination at the two LoxP sites had occurred to excise the large B2 kb 'STOP' cassette containing the Neo gene, bringing together the CMV promoter sequence and the K-ras V12 sequence. This was confirmed by DNA sequencing of this PCR product which showed that the Neo-containing 'STOP' cassette had been deleted between the two NotI sites, leaving only one LoxP site between the CMV promoter and adjacent K-ras sequence (Figure 2 ). The sequencing data also confirmed the presence of valine at codon 12 (substituted for glycine) (Figure 2) . RT-PCR analysis confirmed the expression of human K-ras transcripts in different tissues of K-ras V12 /Cre transgenic mice (but not in K-ras V12 transgenic mice that were negative for Ah-Cre) after b-NF treatment, including expression of both K-ras V12 4A and 4B transcripts in all parts of the gastrointestinal tract (stomach, caecum, all parts of both small and large intestines) and also in liver, pancreas, kidney, lung and spleen, but not in heart or skin ( Figure 3 ). Western blot analysis using anti-Cre antibody showed Cre protein expression in the small and large intestines 5-10 days after b-NF injection (Figure 3 ). Western blot analysis using specific anti-K-Ras V12 protein antibody showed mutant K-Ras protein expressed in the small and large intestines 1 week after b-NF injection in K-ras 
Intestinal phenotypic changes in K-ras
V12
/Cre mice The test group of 28 K-ras V12 /Cre transgenic mice, aged 4-5 weeks, was treated with b-NF to activate Cre expression and K-ras V12 transgene recombination in the small and large intestines and was closely monitored for tumour development. Eight mice were killed after 1 year and 20 mice were monitored for nearly 2 years for signs of intestinal tumour development. During this period, only two intestinal adenomas were detected towards the end of the 2-year period (one in the large intestine and one in the small intestine) in two separate mice, compared with no intestinal tumours in the control B6 mice (n ¼ 16) or Cre-only mice (n ¼ 29) (treated in the same way) over the same 2-year period. No tumours were observed in other tissues in test or control mice. Histological examination of the small and large intestines from the K-ras V12 /Cre transgenic mice showed no evidence of proliferative or differentiation abnormalities (no hyperplastic polyps, no increase in size of the intestinal crypts or villi and no increase in frequency of mitotic figures). The results suggest that conditional expression in the intestines of mutated K-ras does not act as an initiating event in intestinal tumorigenesis in vivo to any significant extent.
Survival and intestinal tumour incidence in K-ras
V12
/Cre/ Msh2 À/À mice To assess the effects of conditional intestinal expression of K-ras V12 on MMR-deficient intestinal tumorigenesis, we crossed K-ras V12 mice with Msh2 À/À mice to derive K-ras V12 transgene construct showing Cre-mediated recombination at the two LoxP sites (c) with excision of the Neo-containing 'STOP' cassette placing the K-ras V12 'minigene' directly under the control of the CMV promoter to activate its expression. The position and orientation of the PCR primers in the CMV promoter and K-ras exon 3 are depicted by arrows. (b) Transgene recombination assay with PCR amplification of genomic DNA, using primers located in the CMV promoter and K-ras V12 exon 3, generated a B500 bp fragment from recombined sequences in the small and large intestines and in stomach, caecum, liver, lung and spleen. Cre, Ah-Cre transgenic mice; K, K-ras V12 transgenic mice; K/C, K-ras V12 /Cre transgenic mice; S1, first half of small intestine nearest stomach; S2, second half of small intestine nearest caecum; L1, first half of large intestine nearest ileum; L2, second half of large intestine nearest anus; Sp, spleen; H, heart; St, stomach; Ce, Caecum; Pan; Pancreas; Sk, skin; Li, liver; Lu, lung. PCR amplification of an APC gene fragment was used to control the quality of genomic DNA samples. (c) DNA sequence data from one of the intestinal-derived B500 bp amplified fragments, using primers located in the CMV promoter and K-ras exon 3, showing that the Neo-containing 'STOP' cassette has been deleted and there is only one LoxP site flanked by two NotI sites and that the K-ras codon 12 sequence is GTT (valine) and not the wild-type GGT (glycine) sequence.
did not differ in terms of the range of sizes observed, tumour stage (there were no invasive adenocarcinomas found) or degree of dysplasia (the adenomas all showed a similar appearance of moderate to severe dysplasia). No evidence of metastatic deposits was found in any of the tumour-bearing mice on examination of liver, lungs, peritoneal surfaces and other organs. None of the b-NF-treated Cre-only (n ¼ 29) or Msh2 þ /À (n ¼ 16) littermate control mice developed intestinal or other tumours within the same period of observation.
The incidence of thymic lymphomas was increased from 16% (4/25) for b-NF-treated Msh2 À/À test mice (Po0.05). There is evidence of transgene recombination and expression of both K-ras4A and K-ras4B in splenic lymphocytes (Figures 2 and 3) , which may explain the increased susceptibility to lymphoma formation. The b-NFtreated K-ras V12 /Cre/Msh2 À/À test mice mostly succumbed to multiple intestinal tumours (occasionally with associated rectal prolapse), causing bowel obstruction and some also had thymic lymphomas which may have partially contributed to their demise. The increased tumour frequency and reduced survival (Figure 5) indicates that K-ras V12 expression can cooperate with Msh2 deficiency to accelerate progression of intestinal tumours as this was associated with a large increase in the number of tumours, particularly in the large intestine as well as in the small intestine.
Analysis of intestinal tumours for expression of K-ras
V12
To determine the proportion of intestinal tumours in which K-ras V12 transgene recombination and K-ras Cre S1 L1 Figure 2 ; Kid, Kidney; 4A, 4A transcript of human K-ras V12 ; 4B, 4B transcript of human K-ras V12 . Both K-ras V12 4A and 4B transcripts are expressed in similar ratios in small and large intestines, stomach, caecum, liver, pancreas, kidney, lung and spleen, but not in skin or heart of b-NF-treated K-ras V12 /Cre transgenic mice. RT-PCR amplification of a b-actin transcript fragment was used to control the quality of RNA samples. (b) Western blot analysis of the expression of either Cre recombinase protein or K-Ras protein using anti-Cre antibody, anti-pan-K-ras antibody or anti-K-Ras V12 antibody in the intestines of K-ras V12 /Cre transgenic mice after b-NF treatment as above. Cre, K/C, L1, S1, as described above; B6, B6 control mice were also treated with b-NF.
K-ras
V12 accelerates Msh2 2/2 intestinal tumours F Luo et al DNA sequencing of the endogenous murine K-ras gene showed two of 10 adenomas (three LITs and seven SITs) from Msh2 À/À mice contained GC-AT transition mutations (at codon 12 of murine K-ras), but no mutations in 17 adenomas (five LITs þ 12 SITs) from K-ras V12 /Cre/Msh2 À/À mice. We also sequenced the hot spot mutation region of B-raf (exon 15), but found no mutations in any of these same two groups of tumours (data not shown).
The expression of K-ras V12 leads to activation MAPK and Akt/PKB pathways To investigate whether expression of K-ras À/À mice. The Akt/PKB protein expression levels showed no obvious change between transgenic and control mice, but levels of both phosphorylated Akt/PKB and phosphorylated glycogen synthase kinase 3b (GSK-3b) were mildly increased in K-ras V12 /Cre small and large intestinal tissues and moderately increased in K-ras V12 /Cre/Msh2 À/À LIT tissue (Figure 7a) . Results suggest that the expression of K-ras V12 leads to activation of both MAPK and Akt/ PKB signaling pathways.
A previous study showed that when the same mutant K-ras V12 transgene was introduced into mouse ES cells, the expression of human K-ras V12 was associated with changes in expression of Pem, Tcl-1 and Trap1a gene transcripts, which were increased 2.9-, 7.4-and 4.3-fold, respectively (Luo et al., (submitted) ). Here, we used RT-qPCR to compare the relative mRNA expression levels of these genes between LITs of b-NF-treated 
V12 accelerates Msh2 2/2 intestinal tumours F Luo et al
V12
/Cre/Msh2 À/À mice and normal intestinal tissue of the Msh2-deficient control mice to show that expression levels of Pem, Tcl-1 and Trap1a gene transcripts were increased by 4.9-, 14.4-and 7.3-fold, respectively, in the LITs known to have recombined and expressed the K-ras V12 transgene (Figure 7b ).
Discussion
Formation of human colorectal neoplasms involves accumulation of genetic and epigenetic changes in a multistep process, including mutational activation of the K-ras proto-oncogene, in the stem cells of intestinal crypts (Fearon et al., 1987 , 2006) . Transgenic expression of mutated K-ras in the small intestine in villus enterocytes under the control of the rat liver fatty acid binding protein gene (Fabp1) promoter caused no tumours, and concern was expressed relating to the lack of expression in stem cells and the short residence time of migrating enterocytes on the villus with exfoliation every 2 to 3 days, possibly allowing insufficient time for accumulation of other genetic mutations (Kim et al., 1993; Janssen et al., 2002 Janssen et al., , 2005 . Transgenic expression of mutated K-ras by the villin promoter has been reported in intestinal stem cells, and these mice have been shown to develop intestinal 
K-ras
V12 accelerates Msh2 2/2 intestinal tumours F Luo et al tumours (Janssen et al., 2002) . K-ras mutation-prone latent alleles (with activation occurring by recombination within the latent allele in random cells) were highly predisposed to a range of tumour types, predominantly early onset lung cancer, but although aberrant crypt foci occurred the transgenic mice failed to develop intestinal tumours, perhaps owing to tissue-specific differences in the frequency of recombination events, or other factors (Johnson et al., 2001; Meuwissen et al., 2001) . Hence, we set out to design and characterize an in vivo model system with inducible expression of mutated K-ras in the stem cells of the intestinal crypt epithelium, using a Cre/ LoxP system.
We generated a transgenic line of mice with a single integrated copy of a K-ras V12 transgene capable of being activated by Cre-mediated recombination at two LoxP sites that spanned a 'STOP' sequence preventing transgene expression in non-recombined cells. This was crossed with mice bearing an Ah-Cre transgene, demonstrated previously to show b-naphthoflavoneinduced intestinal expression of Cre that mediates LoxP recombination in adult intestinal epithelial stem cells of both small and large intestines (Ireland et al., 2004) . The test offspring containing both transgenes were used to investigate the effects of mutated K-ras expression in the intestines upon the initiation or early events in intestinal tumorigenesis in vivo. In contrast to other previous studies, this work introduced a human mutated K-ras 'minigene' capable of expression of both K-ras 4A and K-ras 4B isoforms, as it contains both exons 4A and 4B of the K-ras gene, which has previously been shown to induce more efficient transformation of cells grown in culture (Capon et al., 1983) . The human K-ras protein amino-acid sequence is very highly homologous to that of the mouse. After treating with b-NF, we confirmed intestinal epithelial expression of Cre protein and LoxP recombination by PCR and DNA sequencing. We demonstrated expression of K-ras V12 transcripts (both 4A and 4B) and protein by RT-PCR and Western blot analysis in the small and large intestines and some other tissues. After such induction by b-NF, we detected only a minimal phenotypic change in the intestines of K-ras V12 /Cre mice with just two tumours in the intestines (one adenoma in the large intestine and one adenoma in the small intestine in 20 mice over nearly 2 years (another eight mice were killed after 1 year and showed no intestinal tumours). The appearance of only a very few tumours, consistent with previous studies (Janssen et al., 2002) , and no tumours in other tissues, may reflect the possibility that expression of mutated K-ras in intestinal epithelium may be largely unable to initiate intestinal tumour formation on its own, as it appears to be dependent on cellular context (Guerra et al., 2003) and may need other, possibly multiple, mutations in other genes in the epithelium, and this is consistent with mutated K-ras initiation of intestinal tumorigenesis being a rare or negligible event.
Defective DNA MMR is associated with a markedly increased mutation rate and with initiation and/or acceleration of neoplasia in the intestines and elsewhere, as seen in HNPCC and its Msh2-deficient murine model Transgene recombination and expression of K-ras V12 in intestinal adenomas. (a) Transgene recombination assay with PCR amplification of genomic DNA using primers located in the CMV promoter and K-ras V12 exon 3, generated a B500 bp fragment from recombined sequences in adenomas from the small and large intestines, only if Cre-mediated recombination at the LoxP sites had occurred in the K-ras V12 transgene. LIT1 to LIT9, large intestinal tumours; SIT1 to SIT8, small intestinal tumours. Amplification of a DNA fragment of the APC gene was used as a control for adequate quality of genomic DNA. Arends, 1998; Toft et al., 1999 Toft et al., , 2002 Frayling et al., 2005) . Msh2-deficient mice are predisposed to develop gastrointestinal tumours, thymic lymphomas and some tumours of other organ systems, and although some of the Msh2-deficient mice develop colonic adenomatous polyps, most tumours of the gastrointestinal tract are predominantly found in the small intestine (de Wind et al., 1995 (de Wind et al., , 1998 Toft et al., 1999) . To study the role of mutant K-ras V12 in MMR-deficient intestinal tumour development and progression in vivo, we crossed the K-ras Figure 7 The expression of K-ras V12 leads to activation by phosphorylation of MAPK and Akt/PKB pathway downstream proteins. (a) Western blotting analysis showed p42MAPK and p44MAPK were phosphorylated in large and small intestinal tissues of K-ras V12 / Cre mice and in a LIT of K-ras V12 /Cre/Msh2 À/À mice. Phosphorylated p54JNK and p46JNK were mildly increased in the small intestinal tissues of K-ras V12 /Cre mice and in a LIT of K-ras V12 /Cre/Msh2 À/À mice. There was a mild increase in phosphorylated Raf (Ser 259) in a large intestinal adenoma of K-ras V12 /Cre/Msh2 À/À mice. The expression levels of Akt/PKB protein showed no obvious difference between test and control tissues or tumours, but both phosphorylated Akt/PKB (Ser 473) and phosphorylated glycogen synthase kinase 3b (GSK Ser 9) showed a mild increase in small and large intestinal tissues of K-ras V12 /Cre mice and a moderate increase in a large intestinal adenoma of K-ras V12 /Cre/Msh2 À/À mice. (b) RT-qPCR analysis of the expression of Pem, Tcl-1 and Trap1a genes in three large intestinal adenomas from b-NF treated K-ras V12 /Cre/Msh2 À/À transgenic mice compared to normal large intestinal tissue from Msh2 À/À mice.
K-ras V12 accelerates Msh2 2/2 intestinal tumours F Luo et al identical b-NF treatments to all groups). Thus, K-ras V12 expression cooperates synergistically with Msh2 deficiency in vivo to accelerate progression of intestinal adenomas.
The effect of mutated K-ras on increased progression, but not initiation, of adenoma development was greater in the large intestine relative to the small intestine. Expression of mutated K-ras transcripts (4A and 4B) and proteins in those intestinal tumours showing LoxP recombination was confirmed by RT-PCR and Western blot analysis. Expression of K-ras V12 in intestinal tissues and tumours induced functional activation of both of the MAPK and Akt/PKB pathways, with evidence of phosphorylation of p42MAPK, p44MAPK, p54JNK, p46JNK, Raf, Akt/PKB and GSK-3b. Further evidence of the functional effects of K-ras V12 expression was shown by the demonstration in these tumours of increased expression of Pem, Tcl-1 and Trap1a, which are genes implicated in tumour development and growth that we have shown previously to be increased in expression in ES cells following activation of expression of K-ras V12 (Luo et al.) . However, the precise molecular mechanisms by which mutated K-ras and MMR deficiency interact in vivo to accelerate intestinal tumorigenesis require further study.
Materials and methods
Construction of the conditional K-ras
V12 expressing transgene The conditional K-ras V12 expression transgene construct was generated as follows. The human K-ras V12 'minigene' was derived from plasmid set II K-ras V12 'minigene' (Capon et al., 1983; Brooks et al., 2001) , which contains exons 1, 2, 3, 4A and 4B, together with introns between exons 3, 4A and 4B, such that this K-ras V12 'minigene' is capable of expressing both K-ras 4A and 4B transcripts. The second BamH1 site in the middle of the K-ras V12 'minigene' was destroyed by partial digestion and re-ligation before cloning and the EcoRI-BamHI fragment containing the K-ras V12 'minigene' was cloned into the pBluescript II KS plasmid with a CMV promoter sequence and NotI site upstream of it. Into the NotI restriction enzyme site of this plasmid, between the CMV promoter and the K-ras V12 'minigene', a multi-enzyme linker DNA oligonucleotide containing restriction enzyme recognition sites and two LoxP sites was inserted: NotI-LoxP-HindIII-XhoI-LoxP-NotI (5 0 GGCCGCATAACTTCGTATAGCATACATTATACGA AGTTATAAGCTTATTTGAGGCTCGAGAAATAACTT CGTATAGCATACATTATACGAAGTTATAGCTGGC3 0 ). After digestion with HindIII and XhoI, a 'STOP' cassette element containing a neomycin resistance gene (Neo) was inserted into the HindIII and XhoI enzyme site overhangs. This plasmid was subsequently digested by HindIII and re-ligated in order to excise the HindIII-PKG-HindIII fragment in the construct. Finally, downstream of the K-ras V12 'minigene' a DNA sequence containing an IRES and a gene encoding EGFP was inserted, to generate the final K-ras V12 transgene construct (Figure 1 ). The construct was linearized using BamHI, purified by agarose gel electrophoresis with electroelution, and micro-injected into fertilized FVB/N mouse oocytes to generate founder mice.
PCR-based genotyping of K-ras
V12 mice For genotyping, four pairs of primers for PCR assays were developed for rapid screening of K-ras V12 positive mice (Figure 1 ). RT-qPCR was used to identify the copy number of the K-ras V12 transgene To estimate how many copies of human K-ras V12 transgene were integrated into the mouse genome, RT-qPCR was used to amplify K-ras sequences from both endogenous murine K-ras proto-oncogene and the integrated human K-ras V12 transgene. We designed one pair of primers that bound with identical specificity to both human and mouse K-ras exon 3 sequences: K-ras mouse/human exon 3 sense, 5 0 TTA TTGATGGAGAAACCTGTCTCTTG3 0 , K-ras mouse/human exon 3 antisense, 5 0 TTATGGCAAATACACAAAG AAAGCC3 0 . Briefly, 100 ng DNA from control C57B6/J(B6) and from mice containing the K-ras V12 transgene was used for RT-qPCR, using the iCycler (BioRad, Hercules, CA, USA) starting with denaturation at 95.01C for 3 min, then 35 cycles of 95.01C for 15 s and 60.01C for 1 min. All PCR products were quantitatively analysed in the linear range of the log-plotted exponential phase of PCR amplification. The quantity of the specific K-ras-derived fragments was obtained from standard curves with normalization using the wild-type Apc gene by PCR of the same sample (performed in triplicate).
Generation of K-ras
V12
/Cre mice and Msh2-deficient K-ras V12 /Cre mice K-ras V12 transgene containing mice (on a FVB/N background) were crossed five to seven times with B6 mice, so the K-ras V12 transgene was mainly on B6 background (more than 31/32 proportionally of B6 and less than 1/32 of FVB/N genetic background). These K-ras V12 mice were crossed with Ah-Cre mice, which allow transient intestinal expression of Cre protein, that can mediate recombination of the K-ras V12 transgene, following injection of b-naphthoflavone (b-NF) via the Ah promoter (Ireland et al., 2004) . Subsequently, the K-ras V12 /Cre mice were crossed with Msh2 À/À mice to generate K-ras V12 /Cre/Msh2 À/À triple mutant mice. The mice were genotyped for Msh2 status and for Cre status by PCR assays (Toft et al., 1999; Ireland et al., 2004) .
b-NF-induced expression of Cre and subsequent expression of K-ras
In order to induce Cre expression via the Ah promoter, mice were injected with 16 mg/kg b-NF (Sigma, Dorset, UK) dissolved in warm corn oil, for 6 days (Ireland et al., 2004) . Human K-ras 4A and K-ras 4B expression was determined using human DNA sequence-specific PCR primer pairs: K-ras 4A sense, 5 0 AGTGCAATGAGGGACCAGTACATGAGG3 0 located in K-ras exon 3; and K-ras 4A antisense, 5 0 TTTGCTGATGTTTCAATAAAAGGAATT3 0 located in K-ras exon 4A; K-ras 4B sense, 5 0 GTACCTATGGTCCTAG TAGGAAATAAA3 0 also located in human K-ras exon 3; and
0 located in human K-ras exon 4B. The PCR product sizes for human K-ras 4A and 4B were 267 and 188 bp, respectively. For RT-qPCR, 100 ng of total RNA of different tissue samples was reverse transcribed in 25 ml volume using the iTaq SYBR Green kit RT-PCR kit (Bio-RAD). All PCR reactions were amplified starting with denaturation at 951C for 3 min, then 45 cycles of 951C for 15 s and 601C for 1 min. The specificity of the PCR reactions was determined by 2% agarose gel electrophoresis and PCR of b-actin as quality control of all samples.
PCR analysis of transgene LoxP site recombination and DNA sequencing Genomic DNA was prepared from intestinal tumours and non-tumour gastrointestinal tissue and other tissue samples. The PCR primers used to identify recombination between the CMV promoter and the K-ras transgene were as follows: RE-CMV sense, 5 0 TCAGATCACTAGAAGCTTTATTGCGG3 0 , which is located in the CMV promoter; and RE-K-ras antisense, 5 0 TTCTGAATTAGCTGTATCGTCAAGGC3 0 , which is located in exon 3 of the human K-ras V12 transgene. This PCR assay can detect recombination of the two LoxP sites. The same PCR primers were used as DNA sequencing primers to sequence the PCR product from both termini by standard methods.
Western blot analysis of Ras and Cre protein expression
Fresh tissue samples were lysed in protein lysis buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.5% NP-40) and protease inhibitors were added. Extracts were separated by 15% sodium dodecyl sulphate-polyacrylamide gel electrophoresis, transferred to nitrocellulose filters, and incubated with the corresponding antibodies including anti-pan-K-Ras and anti-K-Ras V12 antibodies (Oncogene Co., Cambridge, MA, USA) and anti-Cre rabbit polyclonal antibody (Novagen, San Diego, CA, USA) (all antibodies were used at 1:1000 dilution). The Phospho-Akt Pathway Sampler kit and the phospho-MAPK Family Antibody Sampler kit (Cell Signaling Technology, Beverly, MA, USA) were used for Western blot analysis of the Akt and MAPK pathway proteins (phospho-p44MAPK, phospho-p38MAPK, phospho-p54JNK, phospho-p46JNK, phospho-Raf (Ser259), Akt, phospho-Akt (Ser473) and Phospho-GSK3beta (Ser9)) according to the manufacturer's protocol. Antibodies were detected with the appropriate goat or rabbit peroxidase-linked secondary antibody and visualization with the NBT/BCIP kit following the manufacturer's instructions (Roche Co, Indianapolis, IN, USA).
Analysis of intestinal tumours
Mice that developed tumours died or were killed when moribund due to tumour burden (mostly due to multiple intestinal tumours, with or without thymic lymphomas). The small and large intestines were carefully dissected. The whole intestinal tract of each mouse was removed, rinsed gently in phosphate-buffered saline using a syringe and opened lengthwise. The opened intestine was spread flat on filter paper, and fixed in 10% neutral-buffered formalin solution. The numbers of intestinal polyps were counted under a dissecting microscope at Â 15 magnification, always by the same investigator. The smallest adenomatous polyps identified were about 0.5-1.0 mm in diameter. Tumours of the small and large intestines and other tissues were processed for paraffin embedding. Sections were prepared for haematoxylin and eosin staining and histological examination for identification of tumour type and stage.
RT-qPCR was used to assess gene expression in intestinal tumours RT-qPCR was carried out to measure the relative levels of Pem, Tcl-1 and Trap1a gene expression using the comparative C t method as previously described (Al-Aynati et al., 2004; Zhu et al., 2004; Luo et al., submitted) . The values for b-actin were used to normalize the gene expression data. 
